MIT Technology Review September 27, 2021
Lindsay Muscato

Booster shots for some Americans were just approved—but core problems around fairness still linger, in the US and around the globe.

The US booster program is about to get underway, after the CDC backed additional shots for a large swath of the American public.

The agency now recommends that people aged 65 years and older, adults in long-term care, and those over 50 with underlying medical conditions get a third Pfizer-BioNTech shot. (Those whose first shot was Johnson & Johnson or Moderna will have to wait a little longer.) Frontline workers or those with a higher risk of infection will also get the chance to get a booster, categories added when the CDC’s director, Rochelle Walensky, overruled her committee.

But...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Interview / Q&A, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID, Trends
Bird Flu H5N1—What We Know So Far About Its Spread To Cows
Should You Worry About The Bird Flu? Here Are The Concerns
Covid-19 Pandemic Led To Growing Acceptance Of Doctors Withholding Treatment
ONC @ 20: A Tale of Optimism and Humility
Europe Strengthens Future Disease Defense

Share This Article